BR0010084A - Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto - Google Patents

Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto

Info

Publication number
BR0010084A
BR0010084A BR0010084-6A BR0010084A BR0010084A BR 0010084 A BR0010084 A BR 0010084A BR 0010084 A BR0010084 A BR 0010084A BR 0010084 A BR0010084 A BR 0010084A
Authority
BR
Brazil
Prior art keywords
retinopathy
compound
inhibit
treat
development
Prior art date
Application number
BR0010084-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Shizue Nakagawa
Yasutaka Nagisa
Hitoshi Ikeda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR0010084A publication Critical patent/BR0010084A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0010084-6A 1999-04-28 2000-04-27 Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto BR0010084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (1)

Publication Number Publication Date
BR0010084A true BR0010084A (pt) 2002-01-15

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010084-6A BR0010084A (pt) 1999-04-28 2000-04-27 Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto

Country Status (23)

Country Link
US (2) US7064141B1 (enExample)
EP (1) EP1197223B1 (enExample)
KR (1) KR100865059B1 (enExample)
CN (1) CN1172719C (enExample)
AT (1) ATE289204T1 (enExample)
AU (1) AU774799B2 (enExample)
BR (1) BR0010084A (enExample)
CA (1) CA2371554C (enExample)
CZ (1) CZ301913B6 (enExample)
DE (1) DE60018186T2 (enExample)
DK (1) DK1197223T3 (enExample)
ES (1) ES2233362T3 (enExample)
HU (1) HU226948B1 (enExample)
MX (1) MXPA01010923A (enExample)
NO (1) NO327446B1 (enExample)
NZ (1) NZ514855A (enExample)
PL (1) PL196895B1 (enExample)
PT (1) PT1197223E (enExample)
RU (1) RU2239454C2 (enExample)
SI (1) SI1197223T1 (enExample)
SK (1) SK286859B6 (enExample)
WO (1) WO2000066161A1 (enExample)
ZA (1) ZA200108527B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical AGENTS FOR IMPROVING THE STATE OF RESISTANCE OF INSULIN
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
KR101087519B1 (ko) * 2003-04-15 2011-11-28 상꾜 가부시키가이샤 안구 내 혈관 신생성 질환의 예방 또는 치료를 위한 의약
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
PT1784181E (pt) 2004-08-31 2013-08-26 Newsouth Innovations Pty Ltd Inibição do vegf
AU2005300787B2 (en) * 2004-11-05 2011-05-26 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
EP1872783B1 (en) * 2005-04-21 2011-12-28 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjunctival disorder
EP1958949A4 (en) * 2005-12-06 2010-04-28 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST HORNHAUT / BINDEHAUT DISEASE
MX2009010167A (es) * 2007-03-28 2009-10-12 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
DE4201554A1 (de) 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
ZA931063B (en) * 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) * 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
ES2243933T3 (es) * 1994-02-08 2005-12-01 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
BR9708336A (pt) * 1996-03-29 1999-08-03 Smithkline Beecham Corp Diidrato de eprosartan e processo para sua produção e formulação
CZ297941B6 (cs) 1996-04-05 2007-05-02 Takeda Pharmaceutical Company Limited Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II
TW416953B (en) * 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ES2182334T3 (es) 1997-06-27 2003-03-01 Smithkline Beecham Corp Monohidrato de eprosartan.
IT1292437B1 (it) 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
TR200000350T2 (tr) * 1997-08-06 2000-12-21 Smithkline Beecham Corporation Eprosartan arginil yüklenmesini-nötrleştirme-kompleksi ve bunun üretim prosesi ve formülasyonu.
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
SI1096932T1 (sl) 1998-07-10 2008-04-30 Novartis Pharma Ag Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) * 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
CA2371554C (en) 2009-06-09
KR20020015315A (ko) 2002-02-27
EP1197223A1 (en) 2002-04-17
KR100865059B1 (ko) 2008-10-23
ZA200108527B (en) 2002-10-17
PL196895B1 (pl) 2008-02-29
HU226948B1 (en) 2010-03-29
AU774799B2 (en) 2004-07-08
NZ514855A (en) 2004-01-30
CN1172719C (zh) 2004-10-27
RU2239454C2 (ru) 2004-11-10
US20060189669A1 (en) 2006-08-24
DK1197223T3 (da) 2005-05-30
AU4143400A (en) 2000-11-17
DE60018186D1 (de) 2005-03-24
WO2000066161A1 (en) 2000-11-09
DE60018186T2 (de) 2005-12-29
ATE289204T1 (de) 2005-03-15
EP1197223A4 (en) 2003-10-29
PL350554A1 (en) 2002-12-16
NO20015257L (no) 2001-10-26
HUP0200890A2 (hu) 2002-11-28
PT1197223E (pt) 2005-04-29
CN1348385A (zh) 2002-05-08
CZ20013804A3 (cs) 2002-04-17
SI1197223T1 (enExample) 2005-08-31
NO327446B1 (no) 2009-06-29
NO20015257D0 (no) 2001-10-26
ES2233362T3 (es) 2005-06-16
CA2371554A1 (en) 2000-11-09
MXPA01010923A (es) 2002-06-21
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
CZ301913B6 (cs) 2010-07-28
HUP0200890A3 (en) 2002-12-28
US7064141B1 (en) 2006-06-20
EP1197223B1 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
BR0315166A (pt) Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
CU23367A3 (es) Formulación de moxifloxacino con sal común
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0111667A (pt) Novos compostos
BR0109703A (pt) Derivados de piperazina
BR9609503A (pt) Composto, uso de um composto, processo de tratamento de condições onde a inibição de pde especìfico para cgmp é de benefìcio terapêutico, em corpo de animal humano ou não humano, composição farmacêutica, e processos para preparar a mesma e um composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
BR0010084A (pt) Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.